聚隆科技(300475.SZ)擬斥3.5億元在深圳設立全資子公司
格隆匯2月5日丨聚隆科技(300475.SZ)公佈,為提升公司市場競爭力,實現公司新一輪戰略佈局和經營目標,公司擬在深圳市投資設立全資子公司—深圳市聚隆景潤科技有限公司(暫定名,最終以工商部門核准登記為準,“新公司”)。擬成立的全資子公司註冊資本為人民幣3.5億元,公司以自有資金出資,佔其全部股權的100%。
深圳市聚隆景潤科技有限公司經營範圍:科技研發、科技生產、科技推廣、技術轉讓、技術諮詢等。
此次投資設立全資子公司是基於公司戰略發展規劃,利用深圳市的區位、人才、技術等資源優勢,進一步完善和優化業務佈局,提升公司綜合競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.